BioRestorative Therapies, Inc.
Filed Nov 18, 2025.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Nov 18, 2025
Contents
Special Cautionary Note Regarding Forward-Looking Statements
Some of the statements in or incorporated by reference into this prospectus contain “forward-looking statements.” Forward-looking statements are made based on our management’s expectations and beliefs concerning future events impacting our company and are subject to uncertainties and factors relating to our operations and economic environment, all of which are difficult to predict and many of which are beyond our control. You can identify these statements from our use of the words “estimate,” “project,” “believe,” “intend,” “anticipate,” “expect,” “target,” “plan,” “may” and similar expressions. These forward-looking statements may include, among other things:
| ● | statements relating to projected growth and management’s long-term performance goals; |
| ● | statements relating to the anticipated effects on results of operations or our financial condition from expected developments or events; |
| ● | statements relating to our business and growth strategies; and |
| ● | any other statements which are not historical facts. |
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements may not be realized due to a variety of factors, including without limitation:
| ● | our current and anticipated cash needs and our need for additional financing; |
| ● | federal, state and foreign regulatory requirements; |
| ● | our ability to conduct clinical trials with respect to our products and services; |
| ● | our ability to develop and commercialize our products and services; |
| ● | our ability to enter into agreements to implement our business strategy; |
| ● | the acceptance of our products and services by patients and the medical community; |
| ● | our ability to secure necessary media and reagents, as well as devices, materials and systems, for our clinical trials and commercial production; |
| ● | our manufacturing capabilities to produce our products; |
| ● | our ability to obtain brown adipose (fat) tissue in connection with our ThermoStem Program; |
| ● | our ability to protect our intellectual property; |
| ● | our ability to obtain and maintain an adequate level of product liability insurance; |
| ● | our ability to obtain third party reimbursement for our products and services from private and governmental insurers; |
| ● | the effects of competition in our market areas; |
| ● | our reliance on certain key personnel; |
| ● | further sales or other dilution of our equity, which may adversely affect the market price of our common stock; and |
| ● | other factors and risks referred to under “Risk Factors” on page 3 of this prospectus. |
You should not place undue reliance on any forward-looking statement. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.